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ABSTRACT
Analysis of the literature on cutaneous leishmaniasis in low-prevalence countries suggests an increase in
imported cases that is attributable to the growing phenomenon of international tourism, migration and
military operations in highly endemic regions. Cases of imported cutaneous leishmaniasis are often
missed initially, but diagnosis can be made non-invasively by PCR using skin scrapings of lesions as
starting material. Cutaneous leishmaniasis is an emerging threat for travellers and should be considered
in all patients presenting with slow-to-heal ulcers.
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Leishmaniasis is a parasitic disease transmitted
by sand ﬂies. It is characterised by a spectrum of
cutaneous, mucocutaneous and visceral clinical
manifestations that depend largely on the species
of parasite involved and the host immune
response. According to recent estimates, 1.5 mil-
lion new cases of cutaneous leishmaniasis (CL)
occur each year. More than 90% of cases occur in
ﬁve countries in the Old World (Afghanistan,
Algeria, Iran, Iraq and Saudi Arabia) and two
countries in the New World (Brazil and Peru) [1].
CL in the Old World is caused by Leishmania
infantum, L. major, L. tropica and L. aethiopica,
which are found in southern Europe, the
Mediterranean basin, the Middle-East and Africa.
CL in the New World is mainly caused by
members of the L. braziliensis complex (L. brazi-
liensis and L. peruviana), L. mexicana, L. amazonen-
sis and the L. guyanensis complex (L. guyanensis
and L. panamensis).
In a prospective study performed during 1991–
93 in a tropical disease unit in Paris, CL was
identiﬁed in 3% of 269 patients with travel-
associated dermatoses, ranking this disease eighth
among all the observed causes of skin disease [2],
while Herwaldt et al. [3] reported 58 imported
cases of New World CL between 1985 and 1990
among travellers from the USA. An apparent
increase in imported CL is indicated by the fact
that at least 108 such cases were described in the
English language scientiﬁc literature between 1999
and 2003, most of which involved travellers and
military personnel (Table 1) [3–12]. Furthermore,
at the beginning of 2004, the USA Department of
Defense reported 522 conﬁrmed cases of CL in
soldiers deployed in south-west ⁄ central Asia [13].
In keeping with this apparent increase, four
imported cases of Old and New World CL were
diagnosed in Milan, Italy during a 16-month
observation period that started in 2001.
The ﬁrst case was an Italian male aged 26 years
who had travelled extensively in Costa Rica and
who presented 2 weeks after his return to Italy
with three cutaneous ulcerated lesions on both
legs. A skin biopsy from the largest ulcer yielded
a positive microscopic diagnosis of amastigotes of
Leishmania spp. which were identiﬁed after
in-vitro culture as L. panamensis. PCR-restriction
fragment length polymorphism (RFLP) analysis
of DNA extracted from skin scrapings of the
lesion identiﬁed the parasite as belonging to the
L. braziliensis complex [14]. The patient was trea-
ted successfully with a course of parenteral
liposomal amphotericin B (total dose, 1800 mg)
and intra-lesional meglumine antimoniate.
The second case was an Italian male aged
63 years who developed two nodular skin lesions
3 months after returning from a 3-week trip to
Tunisia and Morocco. The diagnosis of CL was
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established by microscopy of one of the lesions.
PCR-RFLP analysis of skin scrapings from the
ulcer borders identiﬁed L. major as the causative
agent, with subsequent conﬁrmation after in-vitro
isolation by isoenzyme electrophoretic character-
isation. Meglumine antimoniate treatment was
administered intra-lesionally, resulting in com-
plete healing of a lesion localised to the chest, but
complete resolution of a second lesion on the leg
required an additional 6-week course of oral
itraconazole.
The third case was an Italian male aged
28 years who presented with an ulcerated nose
lesion that appeared a few days after returning
from a 4-week stay in Mexico, where he had
engaged in extensive outdoor activities. Micro-
scopic examination of a skin biopsy revealed
amastigotes of Leishmania spp., and PCR-RFLP
analysis of a skin scraping identiﬁed the
L. braziliensis complex. The patient was treated
with a short course of intravenous pentamidine
isethionate, resulting in complete healing of the
lesion.
The fourth case involved a soldier from
Afghanistan, aged 23 years, who was deployed
in Italy for 2 months and who developed three
cutaneous lesions. Histopathological examination
of an ulcerated foot lesion revealed Leishmania
tissue amastigotes, identiﬁed by PCR-RFLP as
belonging to the L. aethiopica ⁄L. tropica group. The
patient was treated with a short course of intra-
venous pentamidine, resulting in rapid clinical
improvement of all lesions.
CL may present as single or multiple lesions
that generally occur on parts of the body exposed
to sand ﬂy bites. The appearance of the lesions is
quite variable, depending on the species of para-
site involved and on the genetic and immunolo-
gical background of the host. In all four cases
described above, the diagnosis of CL was missed
initially by the general physician, and the patients
had been treated inappropriately with systemic
antibiotics before being referred. Similarly, in the
large retrospective USA study [3], the 58 patients
interviewed had consulted a mean of 2.1 physi-
cians (range, 1–7 physicians) before the diagnosis
of CL was considered, and a median of 112 days
(range, 13–1022 days) elapsed from the time the
lesions were ﬁrst noticed and treatment with
sodium stibogluconate. Since many physicians in
western countries have limited experience of
diagnosing CL in returning travellers, diagnostic
delays and inappropriate management are to be
expected.
In addition to a low awareness of CL among
general physicians, the problem arises of how to
achieve a deﬁnitive diagnosis. Although histo-
pathological examination is useful in excluding
other diagnoses, its sensitivity in diagnosing CL
may only be 14–18% [15–17]. PCR appears to be
the best method for conﬁrming a diagnosis of CL,
with a sensitivity of 98–100% and a speciﬁcity of
100% at the genus level [3,6,10,11]. Faber et al.
[18] compared PCR with traditional diagnostic
techniques (i.e., skin test, culture and histopathol-
ogy) and found that PCR exhibited no signiﬁcant
difference in sensitivity when compared with the
combined results of the three traditional tests, and
had the highest sensitivity when used as a single
diagnostic procedure [18]. In the cases reported
from 1999 to 2003 (Table 1), PCR was positive in
67 of the 68 instances in which it was performed,
while in the four cases described above, it was
possible to readily amplify speciﬁc Leishmania
sequences from skin scrapings of the lesions, thus
avoiding skin biopsies that may be undesirable
when involving certain areas of the body such as
the face. There was complete concordance
between the results obtained by PCR-RFLP and
isoenzyme typing methods.
The ﬁnal issue regarding imported CL is the
choice of therapeutic agent. Factors that may
inﬂuence this decision include: (i) the absence
of evidence-based data regarding travellers;
(ii) the possible high toxicity associated with
parenteral treatment for a benign self-healing
disease (with the exception of New World CL
where there is a risk of mucosal dissemination);
(iii) the compliance of the patient; and (iv) the
lack of availability of appropriate drugs, especi-
ally pentavalent antimonial agents, in certain
countries [19].
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